Authorship and review status
Medical Content & Review: Dr Hakeem Ansar Hussain, Medical Oncologist. Evidence and editorial checking for this addition was performed on 29–30 October 2026. Personal physician review of this version has not been recorded; no last medically reviewed date or individual physician approval is claimed.
Evidence scope
Sources include FIGO 2023, the 2025 ESGO–ESTRO–ESP update, ACOG 2026 bleeding guidance, NCI, FDA, EMA and primary clinical trials. Licensed NCCN and full ESMO professional guidance were not comprehensively accessed; this guide does not claim line-by-line verification against them. The WHO classification is referenced for terminology, not claimed to have been exhaustively reviewed.
How to interpret evidence
Trial populations, comparisons and endpoints differ. PFS is not overall survival; response is not cure. Exploratory molecular subgroups and conference updates are labelled accordingly. Regulatory approval in one country does not establish worldwide availability. Prior immunotherapy changes the relevance of older subsequent-line studies.
Review before medical approval
The clinician should confirm staging boundaries, molecular precedence and variants, 2026 bleeding evaluation, fertility selection, adjuvant risk groups, trial descriptions, regional labels, post-immunotherapy sequencing and every tool branch. Record the reviewed version, actual date, scope and corrections before changing medical-review status.
Educational limitations
These pages do not diagnose, prescribe or replace individualized multidisciplinary care. Tools do not collect identifying details or assign clinical stages. Serious symptoms require direct medical assessment.
References and review status
- NCI: Endometrial Cancer Treatment PDQ
- NCI: Endometrial Cancer Treatment, patient version
- NCI: Endometrial Cancer Prevention PDQ
- NCI: Side Effects of Cancer Treatment
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- Berek et al. FIGO staging of endometrial cancer, 2023
- WHO Classification of Female Genital Tumours, fifth edition, 2020
- ACOG updated postmenopausal bleeding guidance, April 2026
- ACOG Clinical Consensus: EIN / atypical hyperplasia, 2023
- RCOG: Management of Endometrial Hyperplasia, Green-top 67
- ESGO/ESHRE/ESGE fertility-sparing guideline, 2023
- GeneReviews: Lynch Syndrome
- ESGO consensus on endometrial prevention and Lynch syndrome, 2026
- PORTEC-1: fifteen-year outcomes, 2011
- PORTEC-2: ten-year outcomes, 2018
- PORTEC-3: ten-year outcomes and molecular analysis, 2025
- NRG/GOG-258: long-term overall survival, 2025
- RUBY: overall survival analysis, Annals of Oncology 2024
- FDA expanded dostarlimab–chemotherapy indication, August 2024
- FDA pembrolizumab–chemotherapy approval / KEYNOTE-868, June 2024
- FDA durvalumab for dMMR endometrial cancer / DUO-E, June 2024
- EMA: Imfinzi, current European indications
- FDA regular approval of dostarlimab monotherapy / GARNET, 2023
- NRG Oncology: GY018 prolonged follow-up presented at ASCO 2026
- KEYNOTE-775 updated efficacy and safety, JCO 2023
- DailyMed: Lenvima prescribing information
- Fader et al. Trastuzumab in HER2-positive uterine serous carcinoma, 2020
- FDA HER2 IHC 3+ solid-tumour accelerated approval, April 2024
- RAINBO molecularly directed research programme protocol, 2023
- ASCO Palliative Care guideline update, 2024
- DUO-E primary phase III report, JCO 2024
- Eskander et al. NRG-GY018, NEJM 2023
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy